64
gastro-esophageal junction adenocarcinoma
(GATSBY): an international randomised, open-
label, adaptive, phase 2/3 study. Lancet Oncol.
Published Online March 23, 2017. https://
doi.org/10.1016/S1470-2045(17)30111-0- Lordick F, Kang YK, Chung HC et al (2013)
Capecitabine and cisplatin with or with-
out cetuximab for patients with previously
untreated advanced gastric cancer (EXPAND):
a randomised, open-label phase 3 trial. Lancet
Oncol 14:490–499 - Waddell T, Chau I, Cunningham D
et al (2013) Epirubicin, oxaliplatin, and
capecitabine with or without panitumumab
for patients with previously untreated
advanced esophagogastric cancer (REAL3): a
randomised, open-label phase 3 trial. Lancet
Oncol 14:481–489 - Park DJ, Thomas NJ, Yoon C et al (2015)
Vascular endothelial growth factor a inhibition
in gastric cancer. Gastric Cancer 18:33–42 - Ohtsu A, Shah MA, Van Cutsem E et al (2011)
Bevacizumab in combination with chemo-
therapy as first-line therapy in advanced gastric
cancer: a randomized, double-blind, placebo-
controlled phase III study. J Clin Oncol
29:3968–3976 - Hacker UT, Escalona-Espinosa L, Consalvo
N et al (2016) Evaluation of Angiopoietin-2
as a biomarker in gastric cancer: results from
the randomised phase III AVAGAST trial. Br
J Cancer 114:855–862 - Shen L, Li J, Xu J et al (2014) Bevacizumab
plus capecitabine and cisplatin in Chinese
patients with inoperable locally advanced or
metastatic gastric or gastresophageal junc-
tion cancer: randomized, double-blind, phase
III study (AVATAR study). Gastric Cancer
18:168–176 - Fuchs CS, Tomasek J, Yong CJ et al (2014)
Ramucirumab monotherapy for previously
treated advanced gastric or gastresophageal
junction adenocarcinoma (REGARD): an inter-
national, randomised, multicentre, placebo-
controlled, phase 3 trial. Lancet 383:31–39 - Wilke H, Muro K, Van Cutsem E et al (2014)
Ramucirumab plus paclitaxel versus placebo
plus paclitaxel in patients with previously
treated advanced gastric or gastro-esophageal
junction adenocarcinoma (RAINBOW): a
double-blind, randomised phase 3 trial. Lancet
Oncol 15:1224–1235 - Li J, Qin S, Xu J et al (2016) Randomized,
double-blind, placebo-controlled phase
III trial of Apatinib in patients with che-
motherapy-refractory advanced or meta-
static adenocarcinoma of the stomach or
gastresophageal junction. J Clin Oncol
34:1448–1454- Sasore T, Kennedy B (2014) Deciphering
combinations of PI3K/AKT/mTOR path-
way drugs augmenting anti-angiogenic efficacy
in vivo. PLoS One 9:e105280 - Motzer RJ, Escudier B, Oudard S et al (2008)
Efficacy of everolimus in advanced renal cell car-
cinoma: a double-blind, randomised, placebo-
controlled phase III trial. Lancet 372:449–456 - Baselga J, Campone M, Piccart M et al (2011)
Everolimus in postmenopausal hormone-
receptor- positive advanced breast cancer. N
Engl J Med 366:520–529 - Doi T, .Muro K, Boku N et al (2010)
Multicenter phase II study of everolimus in
patients with previously treatedmetastatic gas-
tric cancer. J Clin Oncol 28:1904–1910 - Ohtsu A, Ajani JA, Bai YX et al (2013)
Everolimus for previously treated advanced
gastric cancer: results of the randomized, dou-
ble-blind, phase III GRANITE-1 study. J Clin
Oncol 31:3935–3943 - Kim G, Ison G, McKee AE et al (2015) FDA
approval summary: olaparib monotherapy in
patients with deleterious germline BRCA-
mutated advanced ovarian cancer treated with
three or more lines of chemotherapy. Clin
Cancer Res 21:4257–4261 - Bang YJ, Im SA, Lee KW et al (2015)
Randomized, double-blind phase II trial with
prospective classification by ATM protein
level to evaluate the efficacy and tolerability of
olaparib plus paclitaxel in patients with recur-
rent or metastatic gastric cancer. J Clin Oncol
33:3858–3865 - Bang YJ, Boku N, Chin K et al (2016) Olaparib
in combination with paclitaxel in patients with
advanced gastric cancer who have progressed
following first-line therapy: phase III GOLD
study. Ann Oncol 27(Suppl 6):LBA25 - Niimi T, Nagashima K, Ward JM et al (2001)
Claudin-18, a novel downstream target gene
for the T/EBP/NKX2.1 homeodomain tran-
scription factor, encodes lung- and stomach-
specific isoforms through alternative splicing.
Mol Cell Biol 21:7380–7390 - Lordick F, Schuler M, Al-Batran S-E et al
(2016) Claudin 18.2—a novel treatment tar-
get in the multicenter, randomized, phase II
FAST study, a trial of epirubicin, oxaliplatin,
and capecitabine (EOX) with or without the
antiCLDN18.2 antibody IMAB362 as 1st line
therapy in advanced gastric and gastresophageal
junction (GEJ) cancer. Ann Oncol 27(Suppl
9):ix68–ix85. https://doi.org/10.1093/
annonc/mdw582
Ka-On Lam and Dora L. W. Kwong